Technology

Novo Nordisk is working with authorities in several countries to tackle counterfeit versions of popular diabetes drug semaglutide (Ozempic); Amylyx’s controversial amyotrophic lateral sclerosis (ALS) drug failed to help patients in a large follow-up study; disruptions from the Change Healthcare cyberattack are costing health providers as much as $1 billion a day.

Starting summer 2024, individuals across the US will be able to purchase a continuous glucose monitor (CGM) without needing a prescription.

The poster session at the Americas Committee for Research and Treatment in Multiple Sclerosis (ACTRIMS) Forum 2024 dedicated a section to emerging developments in the use of artificial intelligence (AI) in research and treatment approaches in multiple sclerosis (MS).

On day 2 of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024, speakers gave great attention to novel developments in the field of imaging and 3D modeling in multiple sclerosis (MS).

Mitzi Joi Williams, MD, founder and medical director of Joi Life Wellness Multiple Sclerosis (MS) Center, explains the issue of underrepresentation in MS clinical trials and the potential for digital health technologies to help overcome this barrier.

Stephen Speicher, MD, Flatiron Health, highlights the organization's frameworks for ensuring ethical artificial intelligence (AI) usage, emphasizing the importance of providers and health systems asking critical questions when considering AI tools.

Marisa McGinley, DO, explains how technology can help improve access to multiple sclerosis (MS) care.

Blockage of proposed bill that would protect in vitro fertilization (IVF) reignites debate over reproductive rights and health care access; ransomware attack leaves patients and providers stranded; people 65 years and older should get an additional booster for the COVID-19 vaccine, CDC says.

Survey highlights widespread opposition to Alabama's law restricting in vitro fertilization (IVF) access; investigation focuses on potential anticompetitive practices; Medicare weighs options for implementing a new program to deliver healthy meals to seniors with chronic conditions.

An on-body delivery system approved last fall for paroxysmal nocturnal hemoglobinuria (PNH) has seen rapid uptake and is now being studied for use with isatuximab.

The House Democratic Women’s Caucus wrote a letter urging insurers to comply with both contraceptive coverage requirements and recent Biden administration guidance; several pharmacy chains are experiencing disruptions following a hack at Change Healthcare, UnitedHealth’s technology unit; the FDA said it is not planning to take a tougher stance against clinical trial reporting requirement noncompliance.

Glaucoma specialists were outperformed by a large language model chatbot when it came to diagnostic and treatment accuracy in glaucoma cases.

More than half of US adults have a favorable view of the Affordable Care Act (ACA); smartwatches and rings that claim to measure blood sugar levels without piercing the skin could be dangerous and should be avoided; many believe artificial intelligence (AI) could be the solution to physician burnout.

Discontinuation of asthma drug leaves patients in search of alternative; FDA’s approach to artificial intelligence (AI) raises opportunities and challenges; landmark FDA approval signals hope for millions with severe food allergies.

Medicare beneficiaries are beginning to see the first savings from the Inflation Reduction Act; abortion pills prescribed to patients via telehealth and the mail are safe; nearly half of health care workers have witnessed racism or discrimination in their workplace.

The Federal Trade Commission and HHS will examine generic drug shortage causes; the Biden administration recently dedicated an additional $515 million to a major initiative to study long COVID; cybersecurity experts warn that US hospitals are at risk for attacks and the government is doing little to prevent such breaches.

Expert interviews highlight advancements and challenges in diabetes care technology, including automated insulin delivery systems and continuous glucose monitors, as well as improvements in insurance coverage.

This evaluation looks at a postdischarge digital engagement (PDDE) program using causal inference methods to examine the impact of PDDE on readmission.

This retrospective analysis compared molecular testing outcomes among newly diagnosed cases of metastatic non–small cell lung cancer (mNSCLC) from 2 periods: March 2017 to May 2019 and July 2019 to March 2021.

This systemic review determined telemedicine to be as effective as in-person appointments for the follow-up of patients with atopic dermatitis (AD).

This analysis of Medicare data examines the relationships between fragmented readmission, health information exchange, and repeat imaging in older adults with and without Alzheimer disease.

The authors say their 3D model improves on results using traditional 2-dimensional approaches.

Patients with colorectal cancer (CRC) could participate in telehealth and e-health interventions to promote their sexual health, although efficacy of these interventions needs to be further studied.

Mike Brown, vice president of managed services at Cardinal Health, discusses Cardinal Health's goals to to leverage technology, while reducing costs to the health care system.

Among the 10 patients in the retrospective analysis, the median overall survival after allogeneic hematopoietic stem cell transplantation (allo-HSCT) for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) was 21 months.

Bevey Miner, executive vice president of health care strategy and policy, Consensus Cloud Solutions, discusses the historic progression of health information technology and the role interoperability plays in secure exchanging of patient data.

Mike Brown, vice president of managed services at Cardinal Health, discusses how remote pharmacy services are revolutionizing patient care by improving accessibility and medication safety.

A predictive model utilizing serum metabolic profiles was able to distinguish ovarian cancer from control samples with 93% accuracy, according to a new study.

Separate machine learning models were able to effectively predict both the length of hospital stay and the risk of prolonged hospitalization in people living with HIV.

This new economic valuation of the societal and health care benefits of gene therapy to treat sickle cell disease (SCD) concludes the highly personalized treatment has potential to be cost effective if priced below $2 million.